OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bauer on Rovalpituzumab Tesirine in SCLC

October 4th 2016

Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine in the treatment of patients with small cell lung cancer in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Dr. Sweis on Trend Toward Immunotherapy in GU Malignancies

October 3rd 2016

Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the trend toward immunotherapy in the field of genitourinary malignancies.

Dr. Markman on Important Factors of BSO in Ovarian Cancer

October 3rd 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the most important factors of bilateral salpingo-oophorectomy (BSO) to convey to patients with ovarian cancer.

Dr. Pennell on Unique Treatment-Related Toxicities in Lung Cancer

October 1st 2016

Nathan Pennell, MD, PhD, medical oncologist, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the rare toxicities seen in patients with lung cancer.

Dr. Van Zee on Estimating Risk For Surgical Options in DCIS

October 1st 2016

Kimberly Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the various surgical options for patients with ductal carcinoma in situ.

Dr. Aberle on Novel Approaches to Screening for Lung Cancer

September 30th 2016

Denise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.

Dr. Pirker on New Clinical Trial Designs in Lung Cancer

September 30th 2016

Robert Pirker, MD, Department of Medicine I, Medical University of Vienna, discusses novel clinical trial designs that researchers should use going forward in lung cancer.

Dr. LoRusso on PARP Inhibitors in Triple-Negative Breast Cancer

September 30th 2016

Patricia LoRusso, DO, professor of Medicine (Medical Oncology), associate director, Innovative Medicine, Yale Cancer Center, discusses the role of PARP inhibitors in triple negative breast cancer.

Dr. Dadu on Current Treatment Approaches in Anaplastic Thyroid Cancer

September 30th 2016

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the current treatment approaches being evaluated for patients with anaplastic thyroid cancer.

Dr. Tempero on the HALO 301 Trial for Pancreatic Cancer

September 29th 2016

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the HALO 301 trial, which is exploring the addition of PEGPH20 to gemcitabine and albumin-bound paclitaxel as a potential treatment for patients with pancreatic adenocarcinoma.

Dr. Constantine S. Tam on BCL2 Inhibitors Compared to Ibrutinib, Idelalisib

September 29th 2016

Constantine S. Tam, MD, Consultant Hematologist, Division of Hematology and Oncology, Peter MacCallum Cancer Center, Melbourne, Australia discusses BCL2 inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Anthony on the Pathology of Neuroendocrine Tumors

September 29th 2016

Lowell Anthony, MD, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses the various subtleties in defining the pathology of neuroendocrine tumors.

Dr. Powell on Important Future Directions in Lung Cancer

September 29th 2016

Charles Powell, MD, director, Mount Sinai-National Jewish Health Respiratory Institute, sheds light on what he feels oncologists should be tackling in the future of treating patients with lung cancer.

Dr. Reidy-Lagunes on Sequencing Therapies for Patients With NETs

September 28th 2016

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses sequencing various treatments for patients with neuroendocrine tumors (NETs).

Dr. Yao on Health-Related QOL in Patients With Neuroendocrine Tumors

September 28th 2016

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

Dr. Philip L. McCarthy on Maintenance therapy for Multiple Myeloma

September 28th 2016

Philip McCarthy, BA, MD, professor of oncology and internal medicine director, blood and marrow transplant program, Roswell Park Cancer Institute discusses maintenance therapy for multiple myeloma patients that are eligible for transplant.

Dr. Neal on Exciting Advancements in the Field of Lung Cancer

September 28th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses exciting advancements in the field of lung cancer over the past few years.

Dr. Idos on Remaining Questions With Multiplex Panel Testing

September 28th 2016

Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.

Dr. Gaspar on a Physician Survey on Prophylactic Cranial Irradiation in SCLC

September 28th 2016

Laurie E. Gaspar, MD, professor, Radiation Oncology, University of Colorado Denver, discusses a survey she conducted for physicians on the use of prophylactic cranial irradiation for patients with limited small cell lung cancer.

Dr. Moran on Techniques to Decrease Toxicities With Radiation in Breast Cancer

September 28th 2016

Meena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses some of the techniques that oncologists can use to decrease the toxicities associated with radiation therapy when treating patients with breast cancer.